This article is more than 5 years old. Information may no longer be current.

VIDEO: Incident fractures significantly reduced with abaloparatide

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Paul D. Miller, MD, medical director of the Colorado Center for Bone Research and distinguished clinical professor of medicine at Colorado Health Sciences Center, discusses preliminary results of a clinical trial comparing abaloparatide 80 µ subcutaneous per day with placebo.

The trial also included a third arm of 800 patients assigned to teriparatide 20 µ per day. Both abaloparatide and teriparatide met the primary endpoint for significantly reducing the incidence of vertebral fractures.

According to Miller, this new medication, once it goes through the review process with the FDA, may make medications more available to patients and possibly lower costs.